Skip to content

Study · Systematic review · 2011

2 results

Thymic peptides for treatment of cancer patients.

Wolf E, Milazzo S, Boehm K, Zwahlen M, Horneber M

The Cochrane database of systematic reviews16 Feb 2011Cited by 16 (Europe PMC)

PMID21328265 (opens in a new tab)PMCIDPMC6481824 (opens in a new tab)DOI10.1002/14651858.cd003993.pub3 (opens in a new tab)PepBankPUB-21328265
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with cancer receiving chemotherapy or radiotherapy, pooled trials of thymosin alpha‑1 showed no significant effect on overall survival.

    In plain wordsIn adults with cancer, pooled trials found no significant effect of thymosin alpha‑1 on how long people lived.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeOverall survival (pooled)
    Study

    n: not reported in source

    Comparator
    Placebo or no additional treatment
    Outcome group
    Mortality · Cancer
    Studied dose
    Dose not stated

    Measurements

    Pooled RR for overall survival
    1.21 RR
    thymosin alpha-1

    Source sentences

    Summary
    For thymosin α(1) the pooled RR for OS was 1.21 (95% CI 0.94 to 1.56, P = 0.14)
    1 context sentence
    Summary · context
    Twenty trials investigated pTE (thymostimulin or thymosin fraction 5) and six trials investigated sTP (thymopentin or thymosin α(1)).
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with cancer receiving chemotherapy or radiotherapy, pooled trials of thymosin alpha‑1 showed no significant effect on disease-free survival.

    In plain wordsIn adults with cancer, pooled trials found no significant effect of thymosin alpha‑1 on disease-free survival.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeDisease-free survival (pooled)
    Study

    n: not reported in source

    Comparator
    Placebo or no additional treatment
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Measurements

    Pooled RR for disease-free survival
    3.37 RR
    thymosin alpha-1

    Source sentences

    Summary
    3.37 (95% CI 0.66 to 17.30, P = 0.15) for DFS, with moderate heterogeneity.
    1 context sentence
    Summary · context
    Twenty trials investigated pTE (thymostimulin or thymosin fraction 5) and six trials investigated sTP (thymopentin or thymosin α(1)).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.